• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AnaptysBio Inc.

    5/6/24 12:59:56 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    SC 13G 1 d792368dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. __)*

     

     

    AnaptysBio, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    032724106

    (CUSIP Number)

    April 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Life Sciences Public Fund, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     611,746 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     611,746 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     611,746 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.2% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLSP, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     611,746 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     611,746 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     611,746 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.2% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLSP, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     611,746 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     611,746 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     611,746 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.2% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    Consists of 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Life Sciences Public Overage Fund, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     68,376 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     68,376 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     68,376 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLSP Overage, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     68,376 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     68,376 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     68,376 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLSP Overage, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     68,376 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     68,376 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     68,376 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    Consists of 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Life Sciences X, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     81,772 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     81,772 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     81,772 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 81,772 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLS X, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     81,772 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     81,772 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     81,772 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 81,772 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLS X, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     81,772 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     81,772 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     81,772 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    Consists of 81,772 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Life Sciences XI, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     174,785 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     174,785 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     174,785 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.6% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLS XI, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     174,785 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     174,785 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     174,785 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.6% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHMLS XI, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     174,785 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     174,785 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     174,785 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.6% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    Consists of 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Healthcare VII, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     700,171 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     700,171 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     700,171 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.6% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Frazier Healthcare VII-A, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     199,529 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     199,529 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     199,529 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.7% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of 199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII-A, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHM VII, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     899,700 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     899,700 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     899,700 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     FHM VII, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     899,700 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     899,700 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     899,700 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     James N. Topper

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     80,812 shares (1)

       6.  

     Shared Voting Power

     

     1,836,379 shares (2)

       7.  

     Sole Dispositive Power

     

     80,812 shares (1)

       8.  

     Shared Dispositive Power

     

     1,836,379 shares (2)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,917,191 shares (1)(2)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     7.0% (3)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of 80,812 shares of Common Stock that are held directly by James N. Topper.

    (2)

    Consists of (i) 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 81,772 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (iv) 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. (v) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (vi)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public


      Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.
    (3)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Patrick J. Heron

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     9,110 shares (1)

       6.  

     Shared Voting Power

     

     1,836,379 shares (2)

       7.  

     Sole Dispositive Power

     

     9,110 shares (1)

       8.  

     Shared Dispositive Power

     

     1,836,379 shares (2)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,845,489 shares (1)(2)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     6.8% (3)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consist of 9,110 shares of Common Stock held by The Heron Living Trust 11/30/2004. Patrick J. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power over the shares held by The Heron Living Trust 11/30/2004.

    (2)

    Consists of (i) 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 81,772 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (iv) 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. (v) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (vi)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public


      Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.
    (3)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Albert Cha

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     680,122 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     680,122 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     680,122 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.5% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of (i) 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     James Brush

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     680,122 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     680,122 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     680,122 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.5% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of (i) 611,746 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 68,376 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Daniel Estes

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     174,785 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     174,785 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     174,785 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     0.6% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of 174,785 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Alan Frazier

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     899,700 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     899,700 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     899,700 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Nader Naini

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     0 shares

       6.  

     Shared Voting Power

     

     899,700 shares (1)

       7.  

     Sole Dispositive Power

     

     0 shares

       8.  

     Shared Dispositive Power

     

     899,700 shares (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     899,700 shares (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (2)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Nathan Every

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     4,623 shares (1)

       6.  

     Shared Voting Power

     

     899,700 shares (2)

       7.  

     Sole Dispositive Power

     

     4,623 shares (1)

       8.  

     Shared Dispositive Power

     

     899,700 shares (2)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     904,323 shares (1)(2)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (3)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of 4,623 shares of Common Stock that are held directly by Nathan Every.

    (2)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (3)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    CUSIP No. 032724106

     

     1.   

     Names of Reporting Persons

     

     Brian Morfitt

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States Citizen

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     5,369 shares (1)

       6.  

     Shared Voting Power

     

     899,700 shares (2)

       7.  

     Sole Dispositive Power

     

     5,369 shares (1)

       8.  

     Shared Dispositive Power

     

     899,700 shares (2)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     905,069 shares (1)(2)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     3.3% (2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Consists of 5,369 shares of Common Stock that are held directly by Brian Morfitt.

    (2)

    Consists of (i) 700,171 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii)199,529 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Patrick J. Heron, James N. Topper, Alan Frazier, Nader Naini, Nathan Every and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.

    (3)

    Based on 27,318,644 shares of Common Stock outstanding on April 15, 2024, as set forth in the Issuer’s Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2024.


    Item 1(a).

    Name of Issuer: AnaptysBio, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices: 10770 Wateridge Circle, Suite 210, San Diego, CA 92121

     

    Item 2(a).

    Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

    Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)

    FHMLSP Overage, L.P.

    FHMLSP Overage, L.L.C.

    Frazier Healthcare VII, L.P. (“FH VII”)

    Frazier Healthcare VII-A, L.P. (“FH VII-A”)

    FHM VII, L.P.

    FHM VII, L.L.C.

    Frazier Life Sciences X, L.P. (“FLS X”)

    FHMLS X, L.P.

    FHMLS X, L.L.C.

    Frazier Life Sciences XI, L.P. (“FLS XI”)

    FHMLS XI, L.P.

    FHMLS XI, L.L.C.

    James N. Topper (“Topper”)

    Patrick J. Heron (“Heron”)

    Albert Cha (“Cha”)

    James Brush (“Brush”)

    Daniel Estes (“Estes”)

    Alan Frazier (“Frazier”)

    Nader Naini (“Naini”)

    Nathan Every (“Every”)

    Brian Morfitt (“Morfitt” and together with Topper, Heron, Cha, Brush, Estes, Frazier, Naini and Every, the “Members”)

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The address and principal business office of the Reporting Persons is:

    c/o Frazier Life Sciences Management, L.P.

    1001 Page Mill Rd, Building 4, Suite B

    Palo Alto, CA 94304

     

    Item 2(c).

    Citizenship:

     

       Entities:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    FLSPF

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    FLSPOF

    FHMLSP Overage, L.P.

    FHMLSP Overage, L.L.C.

    FH VII

    FH VII-A

    FHM VII, L.P.

    FHM VII, L.L.C.

    FLS X

    FHMLS X, L.P.

    FHMLS X, L.L.C.

    FLS XI

    FHMLS XI, L.P.

    FHMLS XI, L.L.C.

     

     

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

      

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

    Delaware, U.S.A.

     

       Individuals:

      Topper   -    United States Citizen


       

    Heron

    Cha

    Brush

    Estes

    Frazier

    Naini

    Every

    Morfitt

     

    -

    -

    -

    -

    -

    -

    -

    -

      

    United States Citizen

    United States Citizen

    United States Citizen

    United States Citizen

    United States Citizen

    United States Citizen

    United States Citizen

    United States Citizen

     

    Item 2(d).

    Title of Class of Securities: Common Stock

     

    Item 2(e).

    CUSIP Number: 032724106

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

      

    ☐   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

    (b)

      

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)

      

    ☐   Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

    (d)

      

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)

      

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)

      

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)

      

    ☐   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    (h)

      

    ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)

      

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)

      

    ☐   A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)

      

    ☐   Group, in accordance with §240.13d–1(b)(1)(ii)(K).

       If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:   

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a)

    Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

     

      (b)

    Percent of Class: See Row 11 of cover page for each Reporting Person

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

     

      (ii)

    Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.


    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Each member of the group is identified on Exhibit A to this Schedule 13G amendment.

     

    Item 9.

    Notice of Dissolution of a Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 6, 2024     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
        By: FHMLSP, L.P., its General Partner
        By: FHMLSP, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLSP, L.P.
        By: FHMLSP, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLSP, L.L.C.
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
        By: FHMLSP Overage, L.P., its General Partner
        By: FHMLSP Overage, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLSP OVERAGE, L.P.
        By FHMLSP Overage, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLSP OVERAGE, L.L.C.
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FRAZIER HEALTHCARE VII, L.P.
        By: FHM VII, L.P., its General Partner
        By: FHM VII, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FRAZIER HEALTHCARE VII-A, L.P.
        By: FHM VII, L.P., its General Partner
        By: FHM VII, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer


    Date: May 6, 2024     FHM VII, L.P.
        By: FHM VII, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHM VII, L.L.C.
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FRAZIER LIFE SCIENCES XI, L.P.
        By: FHMLS XI, L.P., its General Partner
        By: FHMLS XI, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLS XI, L.P.
        By: FHMLS XI, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLS XI, L.L.C.
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FRAZIER LIFE SCIENCES X, L.P.
        By: FHMLS X, L.P., its General Partner
        By: FHMLS X, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLS X, L.P.
        By: FHMLS X, L.L.C., its General Partner
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     FHMLS X, L.L.C.
        By:   /s/ Steve R. Bailey
          Steve R. Bailey, Chief Financial Officer
    Date: May 6, 2024     By:   *
          James N. Topper
    Date: May 6, 2024     By:   *
          Patrick J. Heron


    Date: May 6, 2024     By:   *
          Alan Frazier
    Date: May 6, 2024     By:   *
          Nader Naini
    Date: May 6, 2024     By:   *
          Nathan Every
    Date: May 6, 2024     By:   *
          Brian Morfitt
    Date: May 6, 2024     By:   **
          Albert Cha
    Date: May 6, 2024     By:   **
          James Brush
    Date: May 6, 2024     By:   ***
          Daniel Estes
    Date: May 6, 2024     By:   /s/ Steve R. Bailey
          Steve R. Bailey, as Attorney-in-Fact

     

    *

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

    **

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

    ***

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.


    Exhibit Index

    Exhibit A - Agreement regarding filing of joint Schedule 13G.

    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    4/11/2024$56.00Overweight
    Wells Fargo
    3/12/2024$20.00 → $34.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/2/25 6:17:02 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      8/16/24 12:04:31 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

      Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod

      5/5/25 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Anaptys Announces Stock Repurchase Plan

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previ

      3/24/25 9:15:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    SEC Filings

    See more
    • SEC Form 10-Q filed by AnaptysBio Inc.

      10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:19:46 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:17:51 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.

      SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      4/30/25 10:57:53 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      3/27/25 4:10:12 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/15/25 5:04:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/7/25 5:33:21 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 4:00:05 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 9:24:47 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

      SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

      8/16/24 12:07:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on AnaptysBio with a new price target

      Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

      2/4/25 6:58:43 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously

      12/11/24 12:23:14 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by BTIG Research

      BTIG Research downgraded AnaptysBio from Buy to Neutral

      12/2/24 6:53:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Financials

    Live finance-specific insights

    See more

    $ANAB
    Leadership Updates

    Live Leadership Updates

    See more
    • AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

      Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

      5/11/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

      After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

      9/18/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care